| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H28ClN3O2 |
| Molecular Weight | 437.962 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCN1C=C(C(=O)N2CCC3(CC2)OCC4=CC=CC=C34)C5=C1C=C(Cl)C=C5
InChI
InChIKey=QZXVLRCMAHJVIP-UHFFFAOYSA-N
InChI=1S/C25H28ClN3O2/c1-27(2)13-14-29-16-21(20-8-7-19(26)15-23(20)29)24(30)28-11-9-25(10-12-28)22-6-4-3-5-18(22)17-31-25/h3-8,15-16H,9-14,17H2,1-2H3
| Molecular Formula | C25H28ClN3O2 |
| Molecular Weight | 437.962 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
RO-5028442 (RG7713) is a potent and highly selective arginine vasopressin receptor 1A (V1a) antagonist. This compound has been studied for use in autistic spectrum disorder. A phase I study in adult male high-functioning autistic patients has been completed in 2016 and showed that blockade of the V1a receptor may improve social communication in adults with high-functioning ASD. Eye-tracking results showed an increase in biological motion orienting preference. Only mild or moderate adverse events were reported.
